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Abstract
The Tn antigen (GalNAc alpha-O-Ser/Thr) as defined by the binding of the lectin, helix pomatia agglutinin (HPA) or anti-Tn
monoclonal antibodies, is known to be exposed in a majority of cancers, and it has also been shown to correlate positively
with the metastatic capacity in breast carcinoma. The short O-glycan that forms the antigen is carried by a number of
different proteins. One potential carrier of the Tn antigen is immunoglobulin A1 (IgA1), which we surprisingly found in
tumour cells of the invasive parts of primary breast carcinoma. Conventional immunohistochemical analysis of paraffin-
embedded sections from primary breast cancers showed IgA1 to be present in the cytoplasm and plasma membrane of 35
out of 36 individual primary tumours. The immunohistochemical staining of HPA and anti-Tn antibody (GOD3-2C4) did to
some extent overlap with the presence of IgA1 in the tumours, but differences were seen in the percentage of stained cells
and in the staining pattern in the different breast cancers analysed. Anti-Tn antibody and HPA were also shown to
specifically bind to a number of possible constellations of the Tn antigen in the hinge region of IgA1. Both reagents could
also detect the presence of Tn positive IgA in serum. On average 51% of the tumour cells in the individual breast cancer
tumour sections showed staining for IgA1. The overall amount of staining in the invasive part of the tumour with the anti Tn
antibody was 67%, and 93% with HPA. The intra-expression or uptake of IgA1 in breast cancer makes it a new potential
carrier of the tumour associated and immunogenic Tn antigen.
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Introduction
The Tn antigen CD175 is generally defined as (GalNAc alpha-
O-Ser/Thr) or as a cluster of the same glycan. Tn antigen is the
result of an abnormal O-glycosylation. Tumour-associated chang-
es such as the Tn antigen and other changes in O-glycosylation
have been found to be immunogenic and present on a variety of
proteins, e.g. CD43 in T-cell leukaemia cells [1], MUC-1 in colon
cancer [2], CD44 in breast carcinoma [3] and nucleolin in
melanoma [4]. The majority of all carcinomas, 80–90%, are
positive for the Tn antigen as defined by the lectin HPA.
Furthermore, up-regulation of the Tn antigen in tumours is
associated with poor prognosis [3,5,6,7]. Previously HPA affinity
chromatography of a number of solubilised breast cancer tumours
followed by SDS-PAGE and peptide sequencing have identified a
major Tn-carrying 55 kDa protein in breast cancer metastatic
tissue lysate as the heavy chain of IgA1 [8]. The O-glycosylation in
IgA1is normally found in the hinge region of immunoglobulin,
which may theoretically carry a maximum of nine O-glycosyla-
tions and it makes IgA1 a potential carrier of Tn antigen and
potential target for an anti-tumour response [9]. The therapeutic
usefulness of an anti-Tn antibody in passive immunotherapy has
been illustrated in vivo with different animal models. Treatment
with the anti Tn antibody GOD3-2C4 of SCID mice grafted with
a human tumour cell line significantly reduced the growth rate of
the tumor and when combined with cyclophosphamide another
chimeric anti Tn antibody induced complete rejection of a murine
mammary tumor in immune competent animals [10,11].
We have performed a short study that demonstrates high
frequency of IgA1 positive cells in primary breast tumours. IgA1
was found to be present in both the cytoplasm and plasma
membrane of 35 out of 36 individual breast cancer tumours The
percentage and intensity of staining correlated to some extent with
the staining intensity patterns of HPA and GOD-2C4 indicating,
as expected, that IgA1 is not the only protein that carries the Tn
antigen in the tumour. We also demonstrate in this study that
HPA and anti Tn antibody GOD3-2C4 bind different glycoforms
of the GalNAc alpha-O-Ser/Thr in the hinge region of IgA.
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Materials and Methods
Reagents and cell lines
The monoclonal M4D8 anti-human IgA1 [12] was obtained
from Margaret Goodall at The Division of Immunity & Infection
University of Birmingham B15 2TT United Kingdom ., the anti-
human poly-Ig receptor- (pIgR] biotinylated antibody BAF2717,
from R&D Systems Europe Ltd (Abingdon, United Kingdom),
and the negative control mouse IgG from Jacksson ImmunoR-
esearch Europe Ltd (Suffolk, United Kingdom) . The anti-Tn
monoclonal antibody GOD3-2C4 was produced in-house [10].
The biotinylated lectin, HPA, was purchased from EY Labora-
tories, Inc. (San Mateo, CA, USA). T47D and MCF-7 breast
carcinoma cell lines were obtained from the American Type
Culture Collection (ATCC).
Immunohistochemistry
Briefly, the tissue sections (4 mm) were de-paraffinized in xylene
and rehydrated stepwise in ethanol and distilled water. Before
staining, the sections were treated with antigen retrieval buffer
(S1699, Dako, Glostrup, Denmark) in a 2100-Retriver (PickCell
Laboratories, HistoLab, Va¨stra Fro¨lunda, Sweden). The slides
were then allowed to cool for at least 20 min. An automated
immunostainer (TechMate 500Plus, Dako) was used for the
staining procedure: 30 minutes’ staining for the primary antibody
M4D8 anti-human IgA1 (dilution 1:2000), the anti-human pIgR-
biotinylated antibody (dilution 10 mg/mL), the negative control
mouse IgG (dilution 10 mg/mL), GOD3-2C4 (dilution 10 mg/mL),
biotinylated HPA (dilution 25 mg/mL) and the secondary
antibody. Staining was visualized with the EnVision TM
Detection system (K5001 for the biotinylated antibodies and
K5007 for the other antibodies, Dako, Denmark). The slides were
counterstained with haematoxylin.
The percentage of invasive tumour cells stained in each slide
was evaluated on a continuous scale (0–100%). Staining intensity
was assessed semi-quantitatively: 0 = completely negative slide,
1 = weak, 2 = moderate and 3 = strong intensity. Magnifications
ranging from 4 to 40 times were used during scoring. The
histological grade was assessed according to Elston et al. [13]. The
majority of the tumours were invasive ductal breast cancers.
Sample 6 was classified as mucinous and sample 35 as tubular
cancer. Samples 2 and 35 were recidiv, while the remainder of the
tumours were primary lesions.
Microarray analysis
The fine specificity of GOD3-2C4 and HPA for different Tn
antigens was analysed using a glycopeptide array. The assay was
performed as described previously [14], with a synthetic screening
microarray platform with O-glycosylated 20-amino-acid sequences
from the hinge region of the IgA. Briefly, the construction of the
array is based on chemical solid-phase glycopeptide synthesis and
selective the enrichment of defined glycopeptide on a hydrogel-
coated microarray glass slide. Each slide contains the glycopep-
tides given in Table 1. Peptide no.1 is the non-glycosylated peptide
representing the background binding. Each slide was incubated for
one hour with 10 mg/mL GOD3-2C4 or HPA in PBS, pH 7.4.
The GOD3-2C4 antibody was detected with Cy3-conjugated goat
anti-mouse IgG (H+L) (Jackson ImmunoResearch Laboratories,
Inc., (Suffolk, United Kingdom) diluted 1:1000. The biotinylated
HPA was detected with streptavidin-Alexa Fluor 488 (Invitrogen,
Carlsbad, CA, USA; diluted 1:5000). All incubation steps were
separated by two washing steps in PBS containing 0.05% Tween-
20 and one washing step in PBS. After the final washing step, the
slides were rinsed in water and air dried. Finally, the slides were
Table 1. The 44 different IgA hinge glycopeptides tested
with Helix Pomatia Lectin and anti-Tn antibody.















































Bold and S and T indicate O-glycosylation with Ga1NAc.
doi:10.1371/journal.pone.0061749.t001
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scanned (Pro Scan Array HT Microarray, Perkin Elmer Life and
Analytical Sciences, MA, USA) and analysed using image analysis
software (Scan Array Express, v 3.0, Perkin Elmer Life and
Analytical Sciences).
Cell culturing
The human carcinoma cell lines MCF-7 and T47D were
purchased from the ATCC (Rockville, MD, USA) and cultivated
at 37uC in RPMI 1640 supplemented with 10% FCS.
ELISA
Binding to IgA was tested with a sandwich ELISA using HPA,
GOD3-2C4 or polyclonal anti-IgA as a catcher antibody. White
96-well test plates (Lumitrac 600, Greiner-Bio One, Frickenhau-
sen, Germany) were coated with 50 mL of 2 mg/mL antibody or
lectin in 0.1 M sodium carbonate buffer, pH 9 at +4uC overnight.
All following washing steps and dilution of reagents were
performed with PBS containing 0.05% Tween 20. The plates
were washed and then incubated for one hour with 50 mL of
diluted (1:5) conditioned culture supernatants, medium or serum.
After washing, bound IgA1 antibody was detected with HRP-
conjugated rabbit anti-IgA (P-0216; DAKO). After the final
washing step the bound antibody was visualized with SuperSignal
Femto Maximum substrate for chemiluminescence for ELISA
detection (Thermo Scientific, USA). The plates were read on a
Wallac Victor II Fluorescence plate reader (PerkinElmer, USA).
Table 2. Summary of Histological Immunohistochemical Results.
Sample Hormone receptor Histology grade IgA1, % Int. pIgR, % Int. HPA, % Int. Tn, % Int.
1 2 2 40 2 40 2 100 1 80 2
2 + 3 40 3 40 3 100 2 60 2
3 + 3 30 1 1 1 100 2 90 3
4 + 1 80 3 60 1 100 2 100 2
5 + 2 60 3 0 0 50 3 30 3
6 + 1 5 2 0 0 100 2 0 0
7 2 2 80 3 20 2 100 1 10 1
8 + 3 50 3 80 3 100 3 70 3
9 + 3 20 3 10 3 90 2 60 2
10 + 1 20 3 70 3 90 1 20 2
11 2 1 30 2 10 3 100 1 10 3
12 + 3 2 1 5 3 100 3 70 2
13 + 2 70 2 60 2 100 3 90 2
14 + 3 80 3 0 0 80 1 70 1
15 + 1 90 3 50 2 100 3 100 2
16 + 1 50 2 20 1 100 2 90 2
17 + 1 30 3 1 1 90 2 30 3
18 + 2 50 2 40 1 50 1 30 2
19 + 2 10 1 30 3 100 3 80 3
20 + 3 40 2 1 1 100 3 100 3
21 2 3 1 2 0 0 60 2 20 2
22 + 1 50 2 50 2 100 3 90 3
23 + 2 80 3 60 1 100 3 100 3
24 + 1 60 2 30 2 100 2 100 2
25 + 2 80 2 10 1 100 2 30 2
26 + 1 50 1 5 1 80 1 90 1
27 + 3 10 1 20 2 100 3 70 3
28 2 2 100 3 5 1 100 3 100 3
29 2 1 70 2 60 1 100 1 50 2
30 2 3 95 2 20 2 100 3 90 2
31 + 2 60 2 80 1 100 2 100 2
32 + 3 90 2 10 1 90 1 1 1
33 + 2 0 0 0 0 100 2 100 1
34 0 3 90 2 30 3 100 2 100 2
35 + 1 50 2 20 3 80 1 90 1
36 + 3 70 3 40 2 100 3 90 3
Intensity = Int., Hormone receptor =Oestrogen and progesterone receptors.
doi:10.1371/journal.pone.0061749.t002
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Ethics statement
This study was approved by the Ethics Committee of Lund
University (LU 240-01).
Results
Paraffin sections from 36 different breast cancer tumours were
stained for IgA1, Tn antigen, pIgR and HPA. A summary of the
results is presented in Table 2. The percentage and intensity of
positive staining of tumour cells in the invasive part of each tissue
section was analysed. Immunostaining with M4D8 (for IgA1),
HPA, pIgR and GOD3-2C4 (for Tn) is compared with non-
binding mouse Ig. The percentage of stained invasive tumour cells
was evaluated on a continuous scale (0–100%), while the relative
intensity of tissue staining was classified as 0–3.
Positive staining for IgA1 was seen in the majority of the breast
cancer sections. Sections morphologically classified as invasive
were more intensely stained than other parts classified as cancer in
situ (Figure 1A). Figures 1 and 2 illustrates four different breast
cancer tumour samples stained with anti-IgA1, showing different
intensity and amounts of stained cancer cells in the invasive part of
the tumour. The percentage of IgA1-positive cells ranged from 0–
100%, with an overall average of 51%. Binding was frequently
seen in both the cytoplasm and plasma membrane of the breast
cancer tumour cells, as can be seen in Figures 1 and 2. Breast
cancer cells in the invasive part also stained positive for binding of
HPA and GOD3-2C4, to varying degrees. All three reagents, anti
IgA1, HPA and GOD3-2C4, showed overlapping staining of
breast cancer tumour cells, but with clear differences in intensity,
proportion and inter-cellular distribution between different breast
cancer tumour sections. The sections also stained positive for
pIgR, one of the receptors for IgA. The majority of the invasive
tumour sections stained positive for both IgA1 and pIgR, but there
was no obvious correlation between the frequency of expression.
Two tumours stained negative for pIgR but still stained intensively
for IgA1 (Samples 5 and 14 in Table 2). Examples of staining
patterns for IgA1, HPA, GOD3-2C4 and pIgR are shown for
three different breast cancer tumour samples in Figures 3, 4, 5, 6,
7, 8. The percentage staining for IgA1 was 40% in the invasive
part of the tumour in Sample 1, 0% in Sample 33 and 95% in
Sample 30 (Figures 3A, 5A and 7A). Forty percent of the cells were
stained for IgA1 and pIgR in tumour Sample 1 (Figures 3A and
4B). The IgA1-negative tumour (Sample 33) showed no staining
for pIgR (Figures 5A and 6B). Ninety-five percent of Sample 30
was stained for IgA1, but much less for pIgR, being only 20%
(Figures 7A and 8B). HPA and GOD3-2C4 staining seems to be
similar to each other in the three different breast cancer tumour
samples shown in Figures 3B, 4A, 5B, 6A, 7B and 8A. However,
this was not the case for all breast cancer tumour samples analysed
(see Table 2). A majority of the invasive tumour cells showed high
intensity staining with HPA, while less intensity and frequency was
seen with the monoclonal GOD3-2C4 antibody.
The anti-Tn antibody, GOD3-2C4, and HPA were also tested
for specific binding to 46 different glycoforms of the Tn antigen
Figure 1. Immunohistochemical staining of breast tumour specimens showing the presence of IgA1 in the invasive part of the
tumour. A) In Sample 2, 40% of the tumour cells in the invasive part were stained with anti-IgA1 with a relative intensity of 3. Strong cytoplasmic and
plasma membrane staining of IgA1 is observed in the invasive part of the section (INV) but only very weak staining in the in situ part (INSU). B) In
Sample 7, 80% of the cells were IgA1-positive with a relative intensity of 3.
doi:10.1371/journal.pone.0061749.g001
Figure 2. Immunohistochemical staining of specimens from individual breast cancer tumours showing the presence of IgA1 in both
lymphocytes and tumour cells. A) A section showing weak positive staining of cancer cells (Can) and intensively stained lymphocytes (lym). B)
Intense anti- IgA1 staining of cancer cells in Sample 28, an ER/PGR-negative tumour in which 100% of the invasive part of the section was regarded as
being maximally stained for IgA1 with an intensity of 3.
doi:10.1371/journal.pone.0061749.g002
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expressed on a microarray platform. Various O-glycoforms of the
20-amino-acid IgA1 heavy-chain hinge region peptide,
VPSTPPTPSPSTPPTPSPSA were tested. GOD3-2C4 shows very
selective binding to peptides expressing two or more adjacent
GalNAc alpha-O-Ser/Thr carbohydrate epitopes while HPA has
a much broader binding pattern allowing binding to single
GalNAc alpha-O-Ser/Thr carbohydrate epitopes (Table 1 and
Figure 9). Using different sandwich ELISAs, we were also able to
show that some healthy blood donors have Tn-positive IgA in the
circulation. However, no IgA was detected in culture supernatant
from two different breast cancer cell lines (Figure 10).
Discussion
Tn antigen expression is correlated with poor prognosis
regarding the metastatic potential of breast cancer [15]. CD44
and MUC-1 are already known to be Tn-positive proteins in
breast cancer [3]. These proteins play a role in adhesion and/or
migration, and it has been suggested that changes in their O-
glycosylation might influence the function and mobility of cancer
cells [16]. Streets et al. [8] found a dominating 55-kDa band in
SDS-PAGE analysis after HPA affinity chromatography of lysate
from metastatic breast cancer tissue. The 55-kDa band was
identified as the heavy chain of IgA1. They also reported that IgA1
extracted from normal control tissues bound much less to HPA.
Increased concentrations in serum of human IgG, IgM and IgA
have been reported in patients with epithelial carcinomas [17],
and also the occasional intra-cellular presence of secretory
component and IgA in breast carcinoma [18] but no conclusive
data has been presented. However, when applying a conventional
immunohistochemical technique we found very high amounts of
IgA1 in the majority of breast cancer tissues examined. Thirty five
individual samples out of thirty six tested were positive. The breast
cancer tumour cells in the invasive parts of the tumour were more
frequently IgA1-positive than those in the in situ parts of the
tumour (Figure 1A). Based on our observations, IgA1 expression
or uptake in invasive primary breast cancer cells seems to be a
frequent phenomenon. The presence of IgA in tumour sections
was confirmed in a small number of tissue sections with a
polyclonal anti human IgA reagents (data not shown) There may
be different explanations of the enrichment of IgA1 in tumour
cells, such as specific binding of the antibody to tumour cells [19]
or the active uptake of IgA1. The biological functions of
immunoglobulin IgA1 antibodies depend primarily on their
interaction with cell surface receptors, and several cancer cell
receptors are available for binding and internalization of IgA1. Fc
aRI (CD89), poly-IgR, Fc a/mR, asialo-glycoprotein receptor and
the transferrin receptor [20] all have the capacity to transfer IgA1
into the cell. For some of the breast cancer tumours studied here, a
correlation was seen between the staining intensity (Figures 3A and
4B), or lack of staining (Figures 5A and 6B), between pIgR and
IgA1 in the cancer cells. Some of the breast cancer tumours
stained intensively for IgA1 but much weaker for pIgR (an
example of such a tumour is shown in Figures 7A and 8B). This
could indicate there is at least two different receptors involved or
that the pIgR is down regulated.
A third explanation for the uptake of IgA1 may be the reported
capacity of epithelial cancer cells to express endogenous immu-
noglobulin [21]. There are a number of publications on the
potential of cancer cell lines to produce immunoglobulin and other
B-cell-associated proteins [21]. According to one study, cancer cell
lines have the capacity to express heavy-chain IgA1 [22]. In
previous work using the highly sensitive RT-nested PCR method it
was shown that some cancer cell lines transcribe both immuno-
globulin and T-cell receptor genes [23]. Since then, there have
been reports of several cancer cell lines that express immunoglob-
ulin alpha chains, both in the cytoplasm and in secreted form in
the cultured supernatants of cancer cell lines [22]. Transcription of
the immunoglobulin A1 heavy chain (SNC73), together with the
light k and l chains, has also been detected with RT-nested PCR
and immunohistochemistry in human epithelium-derived tumour
cells, including the breast carcinoma cell line MCF-7 [24]. Using a
Figure 3. Intermediate staining percentage of IgA1-positive tumour cells in Sample 1 compared to staining for HPA. Scale
bar =50 mm A) Anti-IgA1, B) HPA.
doi:10.1371/journal.pone.0061749.g003
Figure 4. Staining with anti-Tn and anti-pIgR in Sample 1. Scale bar =50 mm. A) Anti-Tn, B) Anti-pIgR.
doi:10.1371/journal.pone.0061749.g004
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variety of techniques such as immunohistochemical analysis, in situ
hybridization and laser capture micro-dissection, Qiu et al. have
demonstrated that established epithelial cancer lines including
breast cancer can produce IgG in both cytoplasmic and secreted
forms [25]. However, some of these results are in contrast to
observations made by other researchers. When epithelial cancer
cells were analysed after being sorted with FACS as EpCAM +
cells from cultured cancer cell lines they were found positive for Ig
mRNA but no Ig protein expression could be detected in flow
cytometry, indicating very low protein expression of IgA [26]. We
have obtained similar results when no IgA could be detected in
any of the fixed permeabilized tumour cell line tested using flow
cytometry (data not shown). We could neither detect any IgA
protein in the supernatants from the cultured MCF-7 or T47D cell
lines (Figure 10), as has been claimed previously [27]. Perhaps are
cultivation conditions and the use of very specific sub clones of
cancer cells lines very critical for the production of an efficient
amounts of IgA1 in vitro and the most optimal conditions are only
met in some parts of the tumour ‘‘in vivo’’. Alternatively the major
part of the IgA1 seen in the tumour cells originates from the
tumour uptake of surrounding proteins.
Human IgA1 contains both N- and O-glycosylation sites and
carries nine potential O-glycosylation sites in its heavy-chain hinge
region, but only a maximum of five sites are believed to be
glycosylated [5,9,28]. Each attached O-glycan has a core of
GalNAc alpha-O-Ser/Thr (Tn antigen) typically linked to
galactose and one or two sialic acid residues shielding the Tn
epitope. Abnormally glycosylated IgA1, e.g. Tn-positive IgA1, is
known to play a part in autoimmune diseases such as IgA
nephropathy [29]. In patients with IgA nephropathy abnormalities
in O-glycan biosynthesis result in exposure of the immunogenic
Tn antigen by auto-antibodies, resulting in immune complex
formation and deposition in the kidneys, leading to kidney failure
[29] and it is tempting to think the expression of aberrant O-
glycosylation on IgA1 in a similar way could constitute the target
of an anti-tumour immune response [30].
It has also been suggested by that the presence of immuno-
globulins could be advantageous for a tumour cell. Li et al. [27]
reported that transfecting MCF-7 cells with small interfering RNA
Figure 5. Very low percentage of IgA1-positive tumour cells in tumour Sample 33. Scale bar =50 mm. A) Anti.IgA1, B) HPA.
doi:10.1371/journal.pone.0061749.g005
Figure 6. Staining with anti-Tn and anti-pIgR in Sample 33. Scale bar =50 mm. A) Anti-Tn, B) Anti-pIgR.
doi:10.1371/journal.pone.0061749.g006
Figure 7. High percentage of IgA1-positive tumour cells compared with staining with HPA in tumour Sample 30. Scale bar=50 mm.
A) Anti-IgA1, B) HPA.
doi:10.1371/journal.pone.0061749.g007
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(siRNA) blocking the production of Ig inhibited their growth, and
that the presence of cancerous Ig specifically reduced antibody-
dependent cell-mediated cytotoxicity induced by an anti-human
EGF receptor antibody in a dose-dependent manner, suggesting
that tumour-associated Ig has a protective role. Blocking of the
cancer derived IgA have been shown to suppress growth and
viability of cancer cells [22]. Furthermore, the blocking of this
tumour-derived IgG increased programmed cell death and
inhibited tumour growth in vitro and in xeno-transplants in vivo
[25].The observation that breast cancer cells contain high
amounts of IgA1 in vivo needs further investigations of the origin,
clonality and significance of this tumour associated immunoglob-
ulin. As IgA1 is a potential carrier of the Tn antigen it may provide
a target or a blocking decoy for antibody-based therapy.
GOD3-2C4 is monoclonal antibody specific to the Tn antigen
[10] and it preferentially binds adjacent GalNAc alpha-O-Ser/
Thr epitopes in the hinge region of IgA1, but its binding pattern in
the array also indicates a preference for some amino acid
sequences, indicated by its specificity for inner cluster (glycopep-
tides 16, 28, 29, 30, 31, 41, 42, 44, 45) but not flanking regions
(glycopeptide 23, 24 and 34), (Figure 9B).
GOD3-2C4 also binds different known Tn-positive proteins
from different cancer cell lines, e.g. CD44 and mucins (data not
shown). The difference between the reagents is also seen in the
immunohistochemistry staining patterns of HPA and GOD3-2C4
Figure 8. Staining with anti-Tn and anti-pIgR in Sample 30. Scale bar =50 mm A) Anti-Tn, B) Anti-pIgR.
doi:10.1371/journal.pone.0061749.g008
Figure 9. Helix Pomatia Lectin and GOD3-2C4 (anti-Tn antibody) glycopeptide array. Relative fluorescence signal (RFU). The mean value
of five individual measurements is given for each glycopeptide. The numbers of each specific Tn peptide are listed in Table 1. A) HPA, B) GOD3-2C4.
doi:10.1371/journal.pone.0061749.g009
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which did not always overlap in the breast cancer samples
(Table 2). This could be explained by the difference in fine
specificity of the two reagents (Figure 9), but also because HPA is
known to bind blood group A, while GOD3-2C4 is not cross
reactive [10].
Both HPA and GOD3-2C4 bind the Tn antigen on the IgA1
hinge region and in the case of GOD3-2C4 it is clear that
clustered bis-GalNAc structure are preferred. HPA has of course a
broader reaction pattern. The observation that glycopeptide 20
and 29 are negative might be experimental artifact and has to be
examined further. Although these peptides are glycosylated, it
might very well be that the glycan structure is sterically hindered
by an un-favourable conformation. A recent publication noticed a
similar situation for HPA microarray experiment to IgA hinge
glycopeptide (Fig. 4 in reference [31]). Both reagents also
recognize a portion of the circulating IgA1 proteins in healthy
blood donors.
The anti-Tn antibody has in vitro and in vivo effects on the
growth of tumours, and GOD3-2C4 was the first anti-Tn antibody
to show an in vivo reduction of growth of a xeno-transplanted solid
tumour [10]. A more dramatic and convincing therapeutic effect
was seen with the Tn-antigen-specific chimeric monoclonal
antibody (Chi-Tn, originally denoted 83D4) in a syngeneic breast
cancer tumour when combined with cyclophosphamide [11].
Conclusions
The cytosol and plasma membrane of invasive breast cancer
cells frequently contain IgA1, a carrier of the immunogenic Tn
antigen. The origin and possible function of the observed tumour-
associated IgA1 are unknown, but its relatively high abundance
makes it an interesting biomarker and potential therapeutic target
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